Combining Brentuximab Vedotin with dexamethasone, high-dose cytarabine,
and cisplatin (BV-DHAP) as salvage treatment in paediatric relapsed or
refractory classical Hodgkin lymphoma: two case reports.
Abstract
Hodgkin Lymphoma (HL) is a common malignancy in adolescents. For
relapsed/refractory disease many regimens have been proposed and novel
agents are increasingly used. Brentuximab Vedotin (BV) is an antiCD30
antibody-drug conjugate used as single agent or in combination with
classical regimens mainly in adults, while limited is the experience in
paediatrics. We report here on two boys with aggressive and high-risk
relapsed HL, successfully treated with the BV plus DHAP regimen as
induction salvage treatment. Our experience provides initial real-world
evidence on the use of BV-DHAP as first-line salvage therapy for
high-risk relapsed/refractory HL and expands the current therapeutic
choices.